Previous 10 | Next 10 |
2024-03-08 15:25:00 ET Summary Voyager Therapeutics, a drug delivery specialist focused on AAV vectors for gene therapies, has faced many challenges, including partners walking away from deals, disappointing data, and management changes. The company has recently gained momentum th...
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially ...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development cand...
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 20...
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to be presented at the 2024 International Conference on Alzheimer’s and Park...
2024-02-13 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on Februar...
2024-02-03 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-05 12:31:54 ET Gainers: Revelstone Capital Acquisition Corp ( RCAC ) +90% . Ainos ( AIMD ) +72% . Banzai International ( BNZI ) +62% . Safe and Green Development ( SGD ) +41% . Swvl Holdings ( SWVL ) +41% . Zoomcar Ho...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...
- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development candidates selected for Neurocrine-partnered GBA1 and Friedreich ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...